文献速递细胞病理与分子病理神经与头颈病理

ThyroSeq v3在Bethesda IV类甲状腺结节中的恶性概率与分子改变

Probability of malignancy and molecular alterations as determined by ThyroSeq v3 genomic classifier in Bethesda Category IV.
PubMed 文献 · Cancer Cytopathol · 2023-06-26

本研究纳入92例Bethesda IV类甲状腺细针穿刺样本,分为滤泡性肿瘤(FN,46例)和嗜酸细胞性滤泡性肿瘤(OFN,46例),采用ThyroSeq v3检测分子改变并计算分子衍生恶性风险(MDROM)和恶性风险(ROM)。结果显示BIV总体MDROM为34.3%,OFN的MDROM和ROM均呈低于FN的趋势,且RAS突变在FN中显著更常见,染色体拷贝数改变在OFN中更常见。

要点

  • BIV结节中FN与OFN的分子改变谱不同,RAS突变多见于FN,拷贝数改变多见于OFN。
  • OFN的MDROM和ROM均呈低于FN的趋势,但差异未达统计学显著。
  • ThyroSeq v3有助于BIV亚分类的分子风险分层。

核心结论

  • OFN的MDROM和ROM呈低于FN的趋势,且OFN与FN的分子改变存在差异。

研究设计与样本

  • 回顾性研究,纳入92例Bethesda IV类甲状腺细针穿刺样本,分为46例FN(15例伴细胞学异型性、31例不伴)和46例OFN,结合ThyroSeq v3结果与手术随访分析。

主要发现

  • 良性呼叫率和阳性呼叫率分别为49%和51%。
  • BIV总体MDROM为34.3%,OFN中呈低于FN的趋势。
  • RAS突变在FN中显著多于OFN(p = .02)。
  • 染色体拷贝数改变在OFN中多于FN(p < .01)。
  • 组织学随访中OFN的ROM呈低于FN的趋势(p = .1),OFN最常见为嗜酸细胞腺瘤,FN最常见为滤泡型甲状腺乳头状癌。

关键数值与推荐

  • MDROM在BIV为34.3%。
  • RAS突变频率FN vs OFN的p = .02。
  • 染色体拷贝数改变频率OFN vs FN的p < .01。
  • ROM在OFN vs FN的p = .1。

临床怎么用

  • 对BIV结节可结合ThyroSeq v3分子分型辅助区分FN与OFN并评估恶性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ThyroSeq molecular testing assesses the probability of malignancy (POM) in thyroid fine-needle aspiration cytology (FNAC) with indeterminate cytology. The aim was to investigate whether Bethesda category IV (BIV) subcategories are associated with specific molecular alterations, molecular-derived risk of malignancy (MDROM), and risk of malignancy (ROM). METHODS: FNAC slides, associated ThyroSeq, version 3, Genomic Classifier results, and surgical follow-up were retrieved for BIV nodules. Nodules were subcategorized as follicular neoplasm (FN) with or without cytologic atypia or oncocytic follicular neoplasm (OFN). The MDROM, ROM, and frequency of molecular alterations in FN and OFN were analyzed. p < .05 was considered significant. RESULTS: A total of 92 FNAC were identified and subcategorized into 46 FN (15 with and 31 without cytologic atypia) and 46 OFN. The benign call rate and the positive call rate were 49% and 51%, respectively. The MDROM in BIV was 34.3%, trending lower in OFN than in FN. RAS mutations were significantly more frequent in FN when compared to OFN (p = .02). Chromosomal copy number alterations were more often present in OFN than in FN (p < .01). On histologic follow-up, ROM in OFN was trending lower than in FN (p = .1). The most common diagnosis in OFN was oncocytic adenoma, whereas follicular variant papillary thyroid carcinoma was most common in FN. CONCLUSIONS: The MDROM and ROM were trending lower in OFN compared with FN, and the molecular alterations differed between OFN and FN subcategories.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Tjendra Y, Kerr DA, Zuo Y, et al. Probability of malignancy and molecular alterations as determined by ThyroSeq v3 genomic classifier in Bethesda Category IV. Cancer Cytopathol. 2023. PMID: 37358081. doi:10.1002/cncy.22737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。